Article info

Download PDFPDF

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?

Authors

  • Matteo Lambertini Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium PubMed articlesGoogle scholar articles
  • Giulia Viglietti Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium PubMed articlesGoogle scholar articles
  • Evandro de Azambuja Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Matteo Lambertini; matteo.lambertini85{at}gmail.com
View Full Text

Citation

Lambertini M, Viglietti G, de Azambuja E
Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?

Publication history

  • Received March 6, 2018
  • Accepted March 7, 2018
  • First published March 29, 2018.
Online issue publication 
March 29, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.